» Articles » PMID: 33974173

Structure-Based SAR in the Design of Selective or Bifunctional Nociceptin (NOP) Receptor Agonists

Overview
Journal AAPS J
Specialty Pharmacology
Date 2021 May 11
PMID 33974173
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

The nociceptin opioid receptor (NOP), the fourth member of the opioid receptor family, and its endogenous peptide ligand, nociceptin or orphanin FQ (N/OFQ), play a vital role in several central nervous system pathways regulating pain, reward, feeding, anxiety, motor control and learning/memory. Both selective NOP agonists as well as bifunctional agonists at the NOP and mu opioid receptor (MOP) have potential therapeutic applications in CNS disorders related to these processes. Using Surflex-Dock protocols, we conducted a computational structure-activity study of four scaffold classes of NOP ligands with varying NOP-MOP selectivity. By docking these compounds into the orthosteric binding sites within an active-state NOP homology model, and an active-state MOP crystal structure, the goal of this study was to use a structure-based drug design approach to modulate NOP affinity and NOP vs. MOP selectivity. We first docked four parent compounds (no side chain) to determine their binding interactions within the NOP and MOP binding pockets. Various polar sidechains were added to the heterocyclic A-pharmacophore to modulate NOP ligand affinity. The substitutions mainly contained a 1-2 carbon chain with a polar substituent such as an amine, alcohol, sulfamide, or guanidine. The SAR analysis is focused on the impact of structural changes in the sidechain, such as chain length, hydrogen bonding capability, and basic vs neutral functional groups on binding affinity and selectivity at both NOP and MOP receptors. This study highlights structural modifications that can be leveraged to rationally design both selective NOP and bifunctional NOP-MOP agonists with different ratios of functional efficacy.

Citing Articles

Probing non-peptide agonists binding at the human nociceptin/orphanin FQ receptor: a molecular modelling study.

Gozzi M, Malfacini D, Albanese V, Pacifico S, Preti D, Guerrini R RSC Med Chem. 2025; .

PMID: 39790123 PMC: 11707527. DOI: 10.1039/d4md00747f.


Discovery and structure-activity relationships (SAR) of a novel class of 2-substituted N-piperidinyl indole-based nociceptin opioid receptor ligands.

Meyer M, Doshi A, Polgar W, Zaveri N Bioorg Med Chem. 2023; 92:117421.

PMID: 37573822 PMC: 10491432. DOI: 10.1016/j.bmc.2023.117421.


Attenuated G protein signaling and minimal receptor phosphorylation as a biochemical signature of low side-effect opioid analgesics.

Dasgupta P, Mann A, Polgar W, Reinscheid R, Zaveri N, Schulz S Sci Rep. 2022; 12(1):7154.

PMID: 35504962 PMC: 9065038. DOI: 10.1038/s41598-022-11189-6.

References
1.
Bunzow J, Saez C, Mortrud M, Bouvier C, Williams J, Low M . Molecular cloning and tissue distribution of a putative member of the rat opioid receptor gene family that is not a mu, delta or kappa opioid receptor type. FEBS Lett. 1994; 347(2-3):284-8. DOI: 10.1016/0014-5793(94)00561-3. View

2.
Mollereau C, Parmentier M, Mailleux P, Butour J, Moisand C, Chalon P . ORL1, a novel member of the opioid receptor family. Cloning, functional expression and localization. FEBS Lett. 1994; 341(1):33-8. DOI: 10.1016/0014-5793(94)80235-1. View

3.
Fukuda K, Kato S, Mori K, Nishi M, Takeshima H, Iwabe N . cDNA cloning and regional distribution of a novel member of the opioid receptor family. FEBS Lett. 1994; 343(1):42-6. DOI: 10.1016/0014-5793(94)80603-9. View

4.
Meunier J, Mollereau C, Toll L, Suaudeau C, Moisand C, Alvinerie P . Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor. Nature. 1995; 377(6549):532-5. DOI: 10.1038/377532a0. View

5.
Reinscheid R, Nothacker H, Bourson A, Ardati A, Henningsen R, Bunzow J . Orphanin FQ: a neuropeptide that activates an opioidlike G protein-coupled receptor. Science. 1995; 270(5237):792-4. DOI: 10.1126/science.270.5237.792. View